Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic challenges in managing neuroendocrine tumours treated with peptide receptor radionuclide therapy
2008-007965-22Phase 2Completed
- Sponsor
- UZ Leuven Department of Nuclear Medicine
- Start
- Mar 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 edotreotide in neuroendocrine tumour (NET), sponsored by UZ Leuven Department of Nuclear Medicine. Primary endpoint: Progression of disease. Started Mar 2009; status: completed.
02
Drugs
yttrium-90 edotreotide
03
Conditions
neuroendocrine tumour (NET)
Beyond the preview
Go deeper on 2008-007965-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007965-22.